Charles Romley Alder Wright several hours and produced a more potent, acetylated form of morphine, now called "diamorphine (or diacetylmorphine)", also known as heroin. After Wright's death, Heinrich Dreser, a chemist at Bayer Laboratories, continued to test heroin. Bayer marketed it as an analgesic and 'sedative for coughs' in 1898. When its addictive potential was recognized, Bayer ceased its production in 1913. In 1892, Wright was the first to report the existence of the stoichiometric intermetallic compound AlSb (aluminium antimonide), which is now recognized as a compound semiconductor with potential use in high-frequency, low-power consumption microelectronics applications, as well as gamma radiation detection. In
Drug delivery to the brain permeability was known and labeled them either CNS+ or CNS- for compounds that easily transverse the barrier and those that did not. They then set out to analyze the above factors to determine what is necessary to transverse the blood–brain barrier. What they found was a little surprising; lipophilicity is not the leading characteristic for a drug to pass through the barrier. This is surprising because one would think that the most effective way to make a drug move through a lipophilic barrier is to increase its lipophilicity, it turns out that it is a complex function of all of